Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H1 2015

Description:
Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H1 2015

Summary

This 'Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H1 2015', provides an overview of the Gastroesophageal (GE) Junction Carcinomas's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gastroesophageal (GE) Junction Carcinomas, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastroesophageal (GE) Junction Carcinomas and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by this team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Gastroesophageal (GE) Junction Carcinomas
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Gastroesophageal (GE) Junction Carcinomas and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Gastroesophageal (GE) Junction Carcinomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Gastroesophageal (GE) Junction Carcinomas pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Gastroesophageal (GE) Junction Carcinomas
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Gastroesophageal (GE) Junction Carcinomas pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:

List of Tables
List of Figures
Introduction

REPORT COVERAGE

Gastroesophageal (GE) Junction Carcinomas Overview
Therapeutics Development
Pipeline Products for Gastroesophageal (GE) Junction Carcinomas - Overview
Pipeline Products for Gastroesophageal (GE) Junction Carcinomas - Comparative Analysis
Gastroesophageal (GE) Junction Carcinomas - Therapeutics under Development by Companies
Gastroesophageal (GE) Junction Carcinomas - Pipeline Products Glance

Late Stage Products
Clinical Stage Products

Gastroesophageal (GE) Junction Carcinomas - Products under Development by Companies
Gastroesophageal (GE) Junction Carcinomas - Companies Involved in Therapeutics Development

Amgen Inc.
Aslan Pharmaceuticals Pte. Ltd.
AstraZeneca PLC
Basilea Pharmaceutica AG
Bristol-Myers Squibb Company
Celltrion, Inc.
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
Merck & Co., Inc.
Merck KGaA
Merrimack Pharmaceuticals, Inc.
Ono Pharmaceutical Co., Ltd.
Taiho Pharmaceutical Co., Ltd.
Gastroesophageal (GE) Junction Carcinomas - Therapeutics Assessment

Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type

Drug Profiles
(tegafur + gimeracil + oteracil) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
avelumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BAL-101553 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cabozantinib s-malate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DKN-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
gefitinib - Drug Profile
Product Description
<table>
<thead>
<tr>
<th>Product Name</th>
<th>Drug Profile</th>
<th>Product Description</th>
<th>Mechanism of Action</th>
<th>R&amp;D Progress</th>
</tr>
</thead>
<tbody>
<tr>
<td>GS-5745</td>
<td>Drug Profile</td>
<td>Product Description</td>
<td>Mechanism of Action</td>
<td>R&amp;D Progress</td>
</tr>
<tr>
<td>ipilimumab</td>
<td>Drug Profile</td>
<td>Product Description</td>
<td>Mechanism of Action</td>
<td>R&amp;D Progress</td>
</tr>
<tr>
<td>MK-2206</td>
<td>Drug Profile</td>
<td>Product Description</td>
<td>Mechanism of Action</td>
<td>R&amp;D Progress</td>
</tr>
<tr>
<td>MM-111</td>
<td>Drug Profile</td>
<td>Product Description</td>
<td>Mechanism of Action</td>
<td>R&amp;D Progress</td>
</tr>
<tr>
<td>nimotuzumab</td>
<td>Drug Profile</td>
<td>Product Description</td>
<td>Mechanism of Action</td>
<td>R&amp;D Progress</td>
</tr>
<tr>
<td>nivolumab</td>
<td>Drug Profile</td>
<td>Product Description</td>
<td>Mechanism of Action</td>
<td>R&amp;D Progress</td>
</tr>
<tr>
<td>pertuzumab</td>
<td>Drug Profile</td>
<td>Product Description</td>
<td>Mechanism of Action</td>
<td>R&amp;D Progress</td>
</tr>
<tr>
<td>SNX-5422</td>
<td>Drug Profile</td>
<td>Product Description</td>
<td>Mechanism of Action</td>
<td>R&amp;D Progress</td>
</tr>
</tbody>
</table>
Number of Products under Development for Gastroesophageal (GE) Junction Carcinomas, H1 2015

Number of Products under Development for Gastroesophageal (GE) Junction Carcinomas - Comparative Analysis, H1 2015

Number of Products under Development by Companies, H1 2015

Comparative Analysis by Late Stage Development, H1 2015

Comparative Analysis by Clinical Stage Development, H1 2015

Products under Development by Companies, H1 2015

Gastroesophageal (GE) Junction Carcinomas - Pipeline by Amgen Inc., H1 2015

Gastroesophageal (GE) Junction Carcinomas - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H1 2015

Gastroesophageal (GE) Junction Carcinomas - Pipeline by AstraZeneca PLC, H1 2015

Gastroesophageal (GE) Junction Carcinomas - Pipeline by Basilea Pharmaceutica AG, H1 2015

Gastroesophageal (GE) Junction Carcinomas - Pipeline by Bristol-Myers Squibb Company, H1 2015

Gastroesophageal (GE) Junction Carcinomas - Pipeline by Celltrion, Inc., H1 2015

Gastroesophageal (GE) Junction Carcinomas - Pipeline by Exelixis, Inc., H1 2015

Gastroesophageal (GE) Junction Carcinomas - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015

Gastroesophageal (GE) Junction Carcinomas - Pipeline by Gilead Sciences, Inc., H1 2015

Gastroesophageal (GE) Junction Carcinomas - Pipeline by Merck & Co., Inc., H1 2015

Gastroesophageal (GE) Junction Carcinomas - Pipeline by Merck KGaA, H1 2015

Gastroesophageal (GE) Junction Carcinomas - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015

Gastroesophageal (GE) Junction Carcinomas - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015

Gastroesophageal (GE) Junction Carcinomas - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2015

Assessment by Monotherapy Products, H1 2015

Assessment by Combination Products, H1 2015

Number of Products by Stage and Target, H1 2015

Number of Products by Stage and Mechanism of Action, H1 2015

Number of Products by Stage and Route of Administration, H1 2015

Number of Products by Stage and Molecule Type, H1 2015

Gastroesophageal (GE) Junction Carcinomas Therapeutics - Recent Pipeline Updates, H1 2015

Gastroesophageal (GE) Junction Carcinomas - Dormant Projects, H1 2015

Gastroesophageal (GE) Junction Carcinomas - Discontinued Products, H1 2015

List of Figures

Number of Products under Development for Gastroesophageal (GE) Junction Carcinomas, H1 2015
Number of Products under Development by Companies, H1 2015

Comparative Analysis by Clinical Stage Development, H1 2015

Assessment by Monotherapy Products, H1 2015

Number of Products by Top 10 Targets, H1 2015

Number of Products by Stage and Top 10 Targets, H1 2015

Number of Products by Top 10 Mechanism of Actions, H1 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015

Number of Products by Top 10 Routes of Administration, H1 2015

Number of Products by Stage and Top 10 Routes of Administration, H1 2015

Number of Products by Top 10 Molecule Types, H1 2015

Number of Products by Stage and Top 10 Molecule Types, H1 2015

Ordering:

Order Online - http://www.researchandmarkets.com/reports/3129754/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H1 2015
Web Address: http://www.researchandmarkets.com/reports/3129754/
Office Code: SCD2LPGZ

Product Formats
Please select the product formats and quantity you require:

Quantity
Electronic (PDF) - Single User: [ ] USD 2000
Electronic (PDF) - Site License: [ ] USD 4000
Electronic (PDF) - Enterprisewide: [ ] USD 6000

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof [ ]
First Name: ____________________________________________ Last Name: ________________________________
Email Address: * ________________________________________
Job Title: ____________________________________________
Organisation: _________________________________________
Address: _____________________________________________
City: _______________________________________________
Postal / Zip Code: _____________________________________
Country: _____________________________________________
Phone Number: _______________________________________
Fax Number: _________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
</tbody>
</table>
| Bank Address   | Ulster Bank,  
                 | 27-35 Main Street,  
                 | Blackrock,  
                 | Co. Dublin,  
                 | Ireland. |

If you have a Marketing Code please enter it below:

Marketing Code: ___________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World